EndLyz Therapeutics
Boston, US · Founded 2021 · Delaware corporation · 7 employees on LinkedIn · 2 known investors
Find your way into EndLyz Therapeutics
19 people in our graph share verified history with the EndLyz Therapeutics team — schools, employers, funds. One of them is your warm intro.
Damian Crowtherunlockedknows Joanna Wolak · together at Dementia Discovery (overlapped)
×10knows the team · via Dementia Discovery
knows the team · via EndLyz Therapeutics
Endlyz develops small-molecule disease-modifying therapeutics targeting the ATP13A2 and ATP10B lysosomal transporters to restore endo-lysosomal function and counter neurodegeneration. Its initial focus is genetic subsets of Parkinson's disease, with plans to expand into sporadic Parkinson's and other dementias.
Founders & leadership
JW
Joanna WolakinChief Executive OfficerJoanna Wolak brings over two decades of experience in neurodegeneration research and drug discovery, with expertise in Parkinson's and Alzheimer's disease gained through roles in pharmaceutical R&D, biotech investment, and company operations. She currently serves as an executive officer and director at EndLyz Therapeutics.
JB
Jonathan BehrNamed on SEC filing
JG
John GustofsonNamed on SEC filing
DC
Damian CrowtherNamed on SEC filing
ZK
Zaven KaprielianNamed on SEC filing
Board
LB
JC
Justian Craig FoxBoard director
DL
TE
Timothy EdwardsBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$20.5M disclosed across 2 rounds · 2021–2026
▶$17.3MraisedMay 2026 · 7 investors · OtherRule 506(b)
▶$17.3MraisedMay 2026 · 7 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
- Justian Craig FoxDirector
- Donmienne LeungDirector
- Laurence BarkerDirector
- Timothy EdwardsDirector
- Joanna WolakExecutive Officer, Director
- Offering amount
- $19.7M
- Amount sold
- $17.3M
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.3MraisedJul 2021 · 6 investors · BiotechnologyRule 506(b)
▶$3.3MraisedJul 2021 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan BehrDirector
- Joanna WolakExecutive Officer
- John GustofsonDirector
- Damian CrowtherDirector
- Zaven KaprielianExecutive Officer, Director
- Offering amount
- $6.5M
- Amount sold
- $3.3M
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 9
by search overlap
Altay Therapeutics4 shared keywordsAltay Therapeutics develops small molecule inhibitors targeting transcription factors to treat serious diseases including facioscapulohumeral muscular dystrophy and cancer. The company's pipeline includes oral drug candidates designed as first- or best-in-class therapeutics for oncology and inflammatory conditions.
Amylyx4 shared keywordsAmylyx is a biopharmaceutical company developing novel therapies for diseases with high unmet medical needs. It focuses on solving difficult medical challenges for affected patients and their families.
Xilio Therapeutics4 shared keywordsXilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment. Its approach aims to achieve durable efficacy for cancer patients while avoiding the severe systemic side effects of conventional immuno-oncology agents.
Iolyx4 shared keywordsIolyx is a pharmaceutical company focused on developing treatments for ocular conditions. The company assembles a team of experienced scientists, clinicians, and regulatory experts in drug development and ophthalmology.
Lexeotx3 shared keywordsLexeo is a clinical-stage genetic medicine company developing gene therapies that target the genetic causes of cardiovascular diseases. Based in New York City, it focuses on treatments for heart health and other genetic diseases regardless of prevalence.
Eli Lilly3 shared keywordsEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Elicio3 shared keywordsElicio Therapeutics is a biopharmaceutical company focused on developing therapeutic treatments.
Outlook Therapeutics3 shared keywordsOutlook Therapeutics develops ophthalmic therapies for retinal diseases, including anti-VEGF treatments for conditions such as neovascular (wet) age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion. Its lead product, LYTENAVA (bevacizumab-vikg), is an FDA-approved ophthalmic bevacizumab formulation for adults with wet AMD.
Exelixis3 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Companies competing with EndLyz Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does EndLyz Therapeutics do?
- Endlyz develops small-molecule disease-modifying therapeutics targeting the ATP13A2 and ATP10B lysosomal transporters to restore endo-lysosomal function and counter neurodegeneration. Its initial focus is genetic subsets of Parkinson's disease, with plans to expand into sporadic Parkinson's and other dementias.
- Who are EndLyz Therapeutics's investors?
- EndLyz Therapeutics's investors include Oxford Science Enterprises, Dementia Discovery Fund.
- How much funding has EndLyz Therapeutics raised?
- EndLyz Therapeutics has disclosed $20.5M raised across 2 rounds.
- Where is EndLyz Therapeutics headquartered?
- EndLyz Therapeutics is headquartered in Boston, US.